Purpose of review Diabetic peripheral neuropathy (DPN) is a disabling, highly prevalent complication of both type 1 and type 2 diabetes mellitus (T1DM and T2DM). Large clinical studies support the concept that, in addition to hyperglycemia, components of the metabolic syndrome (MetS) may underlie the pathogenesis of DPN, especially in T2DM. This review will present the evidence supporting the MetS and its individual components as potential causal factors for the development of neuropathy.
INTRODUCTION
Diabetes mellitus is one of the most common diseases worldwide, affecting 420 million people in 2014 at a prevalence of 8.5% in adults. The prevalence of diabetes is increasing in middle-income and low-income countries throughout Asia and Africa, as more calorie dense Western diets are adopted throughout the world [1] .
Diabetic peripheral neuropathy (DPN) is the most common complication of both type 1 and type 2 diabetes mellitus (T1DM and T2DM) and occurs in over half of all individuals with T1DM and T2DM [2] . DPN is associated with pain, falls, disability, and a reduced quality of life [3, 4] . Patients present with distal symmetric polyneuropathy, a slowly progressing and length-dependent, axonal neuropathy. Symptoms present in a stocking and glove-like pattern, beginning in the feet and progressing proximally, with either positive (tingling and pain) or negative (numbness and insensate) symptoms. Neuropathic pain is common, with sharp, burning, and electrical sensations in the feet. Another typical clinical presentation, especially in prediabetes or new-onset T2DM, is small-fiber neuropathy (SFN). Patients report extreme shooting pain, tingling, and dysesthesias in the feet. In DPN, clinical examination most commonly reveals decreased perception of all sensory modalities in the feet with decreased or absent Achilles reflexes. In SFN, there is poor pinprick and temperature discrimination, whereas vibratory sensation, position sense, and reflexes are normal. Other neuropathies that can occur with T1DM and T2DM include autonomic neuropathy, treatment-induced neuropathy, polyradiculoplexus neuropathy, mononeuropathies, and cranial neuropathies [5] .
The development of DPN is complex, with multifactorial pathologic mechanisms, some not fully understood. Although hyperglycemia and the duration of diabetes mellitus play an important role in DPN in T1DM and T2DM patients, other potentially causal factors have been identified, especially in T2DM. In this review, we will discuss the evidence supporting metabolic risk factors for the development of DPN.
EFFECT OF DIABETES MELLITUS ON PERIPHERAL NEUROPATHY
T1DM is most common in children and adolescents and is the result of autoimmune damage to the pancreas and subsequent failure of insulin production. T2DM, on the other hand, occurs most commonly in adults and is secondary to inflammation and insulin resistance in multiple tissues, including muscle, fat depots, and liver. Several perturbations in biochemical pathways leading to damage are present in the peripheral nervous system of patients with T2DM. For example, abnormalities in nerve polyol, hexosamine, and protein kinase C pathways are reported, in parallel with changes in advanced glycation endproducts and poly(ADPribose) polymerase. Separately and in concert, these changes produce nervous system oxidative stress and apoptosis of both neurons and supporting glia [6, 7] .
Clinical studies support the concept that DPN in T1DM and T2DM share both common and divergent mechanisms. Studies in T1DM populations show that enhanced glucose control can substantially reduce the incidence of DPN [8] [9] [10] [11] [12] , whereas long-term poor glycemic control can be a determining factor in rapid DPN development [13 & ]. In contrast, in patients with T2DM, intensive glucose control was only marginally effective at reducing DPN incidence [14] , a finding illustrated by the ACCORD study that followed 10 251 patients with T2DM for 3.7 years. This study used the Michigan Neuropathy Screening Instrument to clinically measure DPN and found no significant difference, only a small risk reduction in T2DM patients receiving intensive glucose therapy [ [17, 18] . Cumulatively, these data indicate that factors in addition to hyperglycemia itself and duration of disease [19, 20] must be considered when evaluating the prevalence, development, and treatment of DPN in patients with T2DM. Table 1 summarizes the positive and negative findings of these aforementioned studies. Reasons for the discrepancies in the studies described above include the likely low effect size of prediabetes on neuropathy in comparison with diabetes, as well as the fact that the negative studies may not have been adequately powered to detect such a small, yet important, effect. Furthermore, the populations studied were diverse, including different countries, different ages, and different proportions of patients with diabetes, prediabetes, and normoglycemia. For example, one of the negative studies was performed in an elderly population where prediabetes may have less importance. Finally, the definitions of neuropathy were very different in these studies. Studies that were more likely to detect a small fiber predominant neuropathy were more likely to demonstrate an association between prediabetes and neuropathy.
PREDIABETES AND PERIPHERAL NEUROPATHY
In addition to evaluating the prevalence of DPN, some studies further suggest that individuals with prediabetes or early stages of diabetes often present
KEY POINTS
The prevalence of DPN is high in T1DM and T2DM, but the mechanisms of nerve injury are likely quite different.
The metabolic syndrome is associated with neuropathy, and its individual components have also been demonstrated to be associated with this disabling condition. Hyperglycemia is the most established risk factor for neuropathy, but other metabolic components, particularly obesity, are also likely the risk factors.
Age, sex, height, smoking, alcohol use, genetic susceptibility, and gene-environment interactions are also discussed to have an influence on DPN. clinically with SFN [28, 29] . Interestingly, physical exercise and life-style intervention can reverse components of the metabolic syndrome (MetS) in prediabetic patients [30, 31] . In a trial of patients with prediabetes and SFN, life-style intervention led to reversal of SFN, cutaneous reinnervation, and improvement of pain [31] . Nonetheless, due to the persisting uncertainty regarding the role of prediabetes and DPN, further studies to clarify whether treatment of prediabetes improves neuropathy outcomes are needed.
THE METABOLIC SYNDROME AND DIABETIC PERIPHERAL NEUROPATHY
The MetS by definition comprises obesity, insulin resistance, hypertension, hypertriglyceridemia, and dyslipidemia, and its coexistence with diabetes has been described to be associated with the devel [43] . Therefore, weight loss and/or exercise are both potential interventions to prevent and/or improve neuropathy, but future studies are needed to determine which intervention leads to the best patient outcomes.
Dyslipidemia
Dyslipidemia may have a strong impact on DPN due to its contribution to oxidative stress in dorsal root ganglion sensory neurons and endothelial dysfunction [44] . In T1DM, elevated levels of LDL [20,40 & 
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Mediators of diabetic neuropathy Grisold et al. 45, 47, 48] . In a study of patients with mild-to-moderate diabetes, a correlation between the loss of myelinated fiber density and hypertriglyceridemia was observed, independent of disease duration, age, diabetes control, or other variables [49] , suggesting an important influence of elevated triglycerides on the progression of DPN. Likewise, another study demonstrated that lower extremity amputations were more frequent in diabetic patients with elevated triglyceride levels [50] , and lower extremity amputations are known to be highly associated with neuropathy. In contrast to these positive findings, however, Kwai et al. [51] showed that serum triglyceride levels did not influence axonal function in T2DM patients, and other recent studies also did not find an association between elevated triglycerides and DPN [24 && ,25
Similar to the evidence for HDL and LDL and neuropathy, the data supporting hypertriglyceridemia and neuropathy are mixed.
Hypertension
The role of hypertension and DPN is uncertain [19] . In individuals with T1DM, studies have shown an association between high blood-pressure and DPN [20,40 & ]. In T2DM, however, most previous studies have been negative 
OTHER POTENTIAL RISK FACTORS FOR DIABETIC PERIPHERAL NEUROPATHY
In addition to hyperglycemia and the MetS, there are other risk factors that potentially contribute to the development of DPN. Sex appears to influence DPN in T2DM, with male sex being associated with neuropathy [25
& ], although no association was observed in a T1DM population [40 & ]. Age, on the other hand, has long been known to be a risk factor for DPN [19, 22 && ,40 & , 55, 56] ; the prevalence of DPN increases with every decade of life [53, 55] . Potentially due to the length-dependent presentation of DPN, height is also associated with neuropathy [20,25 && ,40 & ,56,57] . Substance abuse has also been linked to DPN risk, with a specific focus on smoking and alcohol use. In T2DM patients, smoking may also be a risk factor [58] ; in a recent study smoking was an independent risk factor, as heavy smokers exhibited worse nerve conduction studies [59] . Likewise, smoking was also significantly associated with DPN in T1DM [40 & ,60] , or exhibited a trend for association [20] . The influence of alcohol consumption, on the other hand, remains uncertain. Although some studies support a link between alcohol consumption and DPN [55, 56] , others show no association [22 && ,58] . One study, however, did report an association between increased ulcerations in diabetic feet and alcohol consumption [61] .
Potential genetic susceptibility to DPN is also suggested through studies reporting an association with several genes, such as ACE, MTHFR, GST, GLO 1, APOE, TCF7L2, VEGF, IL4, GPX1, eNOS, ADRA2B, MIR146A, and MIR128A [62] . Of particular interest are ApoE and TCF7L2, two genes involved in lipid metabolism. Apo E is polymorphic, consisting of ApoE2, ApoE3, and ApoE4, and it is a lipoprotein involved in the metabolism of plasma cholesterol and triglycerides. In a multivariate analysis, the E4-carrier status conferred a more than five-fold increased risk of severe neuropathy in T2DM [63] . Also involved in glucose and lipid metabolism, the TCF7L2 gene encodes a nuclear receptor for B-catenin, which interferes with the Wnt signaling pathway [44] . Studies indicate that variants of the TCF7L2 gene are associated with insulin resistance, reduced insulin secretion, and increased risk of T2DM [64] . In addition, consanguinity and hereditary gene-environment interactions have also recently been determined to have an impact on DPN in an Arabic study [65] .
CONCLUSION
New research has recently increased the available knowledge about possible causes of DPN. Although hyperglycemia clearly plays an important and devastating role in developing DPN in patients with diabetes mellitus, recent literature has also shown that prediabetes and other components of the MetS, particularly obesity, likely play an important role in damaging nerve fibers. In addition, other risk factors, such as genes, age, sex, height, alcohol, and smoking, may also contribute to DPN pathogenesis. These studies highlight the importance and impact of metabolic components and additional risk factors, other than hyperglycemia, on DPN. Given that the current established therapies for DPN only target hyperglycemia, further studies regarding the impact of novel therapies on DPN outcomes, such as weight loss and exercise, are warranted.
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